David Abrams Nuvation Bio Inc. Transaction History
Abrams Capital Management, L.P.
- $3.12 Billion
- Q3 2024
A detailed history of David Abrams (Abrams Capital Management, L.P.) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Abrams Capital Management, L.P. holds 3,811,513 shares of NUVB stock, worth $10.2 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
3,811,513
Previous 3,811,513
-0.0%
Holding current value
$10.2 Million
Previous $11.1 Million
21.23%
% of portfolio
0.28%
Previous 0.39%
Shares
1 transactions
Others Institutions Holding NUVB
# of Institutions
158Shares Held
157MCall Options Held
3.2KPut Options Held
98.7K-
Decheng Capital LLC Menlo Park, CA26MShares$69.6 Million14.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA19.2MShares$51.5 Million1.92% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$43.5 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$35 Million44.61% of portfolio
-
Octagon Capital Advisors LP New York, NY12.2MShares$32.6 Million6.76% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $582M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...